GPhC calls on pharmacies to strengthen safeguards in weight management services.

The General Pharmaceutical Council has published a themed review of its inspection reports and concerns received between January 2024 and December 2025, focused on the supply of weight management medicines through registered pharmacies in Great Britain. The message is not subtle. Many pharmacies are doing this well. A meaningful number are not, and the regulator wants the gap closed.

For any brand or pharmacy supplying GLP-1 receptor agonists or other weight management treatments online, this is the most concrete statement of regulatory expectations we have seen to date. It is worth reading carefully. The full review is published by the GPhC here: Weight management medicines and services: a review of GPhC inspections and concerns (PDF, April 2026).

What the review actually found

The findings are familiar to anyone who has spent time inside a busy direct to patient pharmacy: standards drift under volume. The GPhC's inspectors and concerns intake repeatedly identified the same weaknesses.

• Risk assessments and standard operating procedures that had not been reviewed against current practice.
• Clinical governance arrangements that did not include sufficient oversight of third party prescribers.
• Patient consultation records that were incomplete, inconsistent, or missing entirely.
• No independent verification of weight, height, or BMI, so prescribing decisions rested on self reported data alone.
• Limited consideration of vulnerable groups, including patients with eating disorders.
• Poor communication, and limited arrangements for ongoing clinical follow up and customer support.

What the GPhC is asking for

The recommended actions read as a baseline rather than a stretch target. Pharmacy owners, pharmacy teams, and prescribers are expected to:

1. Maintain robust, regularly reviewed risk assessments and standard operating procedures for weight management services.
2. Operate effective clinical governance and oversight, including appropriate due diligence when working with third party prescribing services.
3. Independently verify clinical information such as weight and height, in line with GPhC guidance.
4. Conduct individual review of clinical suitability, with specific consideration of vulnerable groups including individuals with eating disorders.
5. Thoroughly document all consultations and clinical decision making.
6. Provide clear communication and accessible ongoing support, including safe and secure supply and delivery of medicines.

Roz Gittins, Chief Pharmacy Officer at the GPhC, framed it plainly: "This is about more than compliance. By strengthening governance, enhancing clinical safeguards and improving transparency, pharmacy teams can ensure that the services they provide are safe, reliable and person-centred."

Why this is hard to do at scale

Every one of these expectations is reasonable in isolation. The challenge is delivering all of them, consistently, across thousands of orders a week, while the GLP-1 market continues to expand toward 3.3 million UK patients and an oral tablet enters the mix. Spreadsheets, email threads, and bolted on consultation forms quietly stop holding up at that volume. That is when consultation records go missing, BMI checks get skipped, and prescriber oversight becomes a rubber stamp.

The GPhC review is, in effect, a list of the failure modes that surface when infrastructure has not kept pace with demand.

How Sync-RX is built around these expectations

Sync-RX is the regulated infrastructure that sits between an online storefront and a UK dispensing pharmacy. The platform is designed so that the controls the GPhC describes are the default path, not a manual workaround.

• Treatment specific consultation flows with versioned questions, contraindication logic, and structured capture of clinical information, so consultations are complete and consistent on every order.
• Independent verification of identity through Veriff, with weight, height, and BMI captured and recalculated server side rather than trusted from a free text field.
• Prescriber routing to named, GPhC and GMC registered prescribers, with full visibility of decisions and the ability to request more information, decline, or escalate.
• Eating disorder and vulnerability checks embedded in the clinical logic for weight management treatments, with hard stops where appropriate.
• Full audit trail covering consultation, identity, prescriber decision, dispense, and fulfilment, retained in a form that survives a regulator's review.
• Patient communication and follow up through the patient account and messaging, so ongoing support is a built in part of the service rather than an afterthought.

The practical takeaway

The GPhC has signalled where it will be looking. Brands and pharmacies that treat this review as a checklist, and wire those checks into the order flow rather than the SOP folder, will be in a much stronger position the next time an inspector arrives or a concern is raised. Those that do not are running an operational risk that is now explicitly on the regulator's radar.

If you are scaling a weight management service in the UK and want to see how Sync-RX maps to each of the GPhC's recommended actions, we are happy to walk through it.

Talk to us about your service